improved following on-going cost optimization and FY17 guidance maintained. AIS reported 3Q17 EBITDA of Bt17,589mn, +15% YoY and +2.8% QoQ, mainly due to revenue growth and controlled SG&A. YTD, AIS spent
enable assignment of assess rights; (b) the allocation and use of privileged access rights should be restricted and controlled; (c) the allocation of passwords should be controlled through a formal
assess rights; (b) the allocation and use of privileged access rights should be restricted and controlled; (c) the allocation of passwords should be controlled through a formal management process; (d
processes, including effectively controlled in maintenance cost. Net gain (loss) on exchange rate Q1-2020 Q1-2019 THB Mn THB Mn THB Mn % Net gain (loss) on exchange rate 112.2 (28.3) 140.5 N.A. (>100) Change
Bt41,108mn in 2017 following controlled investment and the negotiation with suppliers for longer payment term. Also, AIS has paid license installments totaling Bt20,536mn to the NBTC. As a result, free cash
decreased by -8.4% YoY. 9M23 EBITDA increased by 4.2% YoY as a result of an improvement in core service revenue and well- controlled SG&A. The net profit closed at Bt22,084mn, surging 18% YoY driven by
(Microsoft Word - \315\270\324\272\322\302\272\3054-1_2_silver 2.doc) 1 .. 54 18 3 : ! "# $ % &'( )* +,# !#-!'( ). /0. 11 23!4 $ !4 .#.$5 6' +6 (options) 0 (forwards) D E (futures) $# + (swaps) +,". (/' "H #II(6.3"H J0# 3 !K$1J0 #IIE3)$ K /0./ .. (). 2 3). 3 )#' 1 "%0) 1. !$+3J6(% #-!'# 4#% "#' 3 (.* % J0!E E0"'/+1 1.1 $1#%I '&+ (substance over form) ' $ E3!E # 3R+3J6 S*2S#" (risks and economic benefits) ) "'3+,#%IJ0/' % ' '1E3&'(&+(0 U (legal form) 6' index options 3 d...
manufacturing cosmeceuticals and modern medicine from FDA and controlled quality and operational efficiency which certified by international standards ISO 9001:2008, GMP, PICS, HACCP และ HALAL. Presently, At-Ze